FIGURE SUMMARY
Title

A novel metabolism-based phenotypic drug discovery platform in zebrafish uncovers HDACs 1 and 3 as a potential combined anti-seizure drug target

Authors
Ibhazehiebo, K., Gavrilovici, C., de la Hoz, C.L., Ma, S.C., Rehak, R., Kaushik, G., Meza Santoscoy, P.L., Scott, L., Nath, N., Kim, D.Y., Rho, J.M., Kurrasch, D.M.
Source
Full text @ Brain
Fig. 1

ZFIN is incorporating published figure images and captions as part of an ongoing project. Figures from some publications have not yet been curated, or are not available for display because of copyright restrictions.

Fig. 2

ZFIN is incorporating published figure images and captions as part of an ongoing project. Figures from some publications have not yet been curated, or are not available for display because of copyright restrictions.

Fig. 3

ZFIN is incorporating published figure images and captions as part of an ongoing project. Figures from some publications have not yet been curated, or are not available for display because of copyright restrictions.

Fig. 4

ZFIN is incorporating published figure images and captions as part of an ongoing project. Figures from some publications have not yet been curated, or are not available for display because of copyright restrictions.

Fig. 5

ZFIN is incorporating published figure images and captions as part of an ongoing project. Figures from some publications have not yet been curated, or are not available for display because of copyright restrictions.

Fig. 6

Vorinostat blocks seizures in zebrafish and rodents. (A) Image shows agarose-embedded zebrafish and the placement of a glass microelectrode in the tectum opticum. Representative extracellular field recordings obtained from the optic tectum of 6 dpf wild-type and kcna1-MO zebrafish larvae ± vorinostat treatment (40 μM). The presence of repetitive high frequency, large amplitude spikes indicative of hyperexcitability in knockdown animals is shown, and is abolished in the presence of vorinostat. (B) Representative electrographic seizure and heat maps recorded in Kcna1-null mice. Bar graph of the mean number of seizures per day recorded from six Kcna1-null mice ± vorinostat treatment. Mice were recorded for 24 h per day for 1 day, and then received vorinostat injection (40 mg/kg body weight/day) for 6 days. Vorinostat treatment significantly reduced the number of seizures (two-way ANOVA, F = 27.7, P < 0.01). (C) Acute (30 min dosing regimen) vorinostat (100 and 300 mg/kg) administration significantly reduced corneal electrode-stimulated seizures by 50 and 75%, respectively. A 2-h dosing regimen effectively reduced seizures across all concentrations used in the 6 Hz psychomotor test but not in the maximum electroshock test.
Fig. 7

ZFIN is incorporating published figure images and captions as part of an ongoing project. Figures from some publications have not yet been curated, or are not available for display because of copyright restrictions.

Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Brain
Your Input Welcome
We welcome your input and comments. Please use this form to recommend updates to the information in ZFIN. We appreciate as much detail as possible and references as appropriate. We will review your comments promptly.
Please check the highlighted fields and try again.
Thank you for submitting comments. Your input has been emailed to ZFIN curators who may contact you if additional information is required.
Oops. Something went wrong. Please try again later.